Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

Détails

ID Serval
serval:BIB_E01969499682
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Périodique
International journal of cancer. Journal international du cancer
Auteur⸱e⸱s
Bay J.O., Ray-Coquard I., Fayette J., Leyvraz S., Cherix S., Piperno-Neumann S., Chevreau C., Isambert N., Brain E., Emile G., Le Cesne A., Cioffi A., Kwiatkowski F., Coindre J.M., Bui N.B., Peyrade F., Penel N., Blay J.Y.
ISSN
0020-7136
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
119
Numéro
3
Pages
706-11
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
Advanced soft-tissue sarcomas are usually resistant to cytotoxic agents such as doxorubicin and ifosfamide. Antitumor activity has been observed for gemcitabine and docetaxel combination. We conducted a retrospective study on 133 patients (58 males/75 females) with unresectable or metastatic soft-tissue sarcoma. The median age at diagnosis was 51.7 (18-82), with 76 patients with leiomoyosarcoma and 57 patients with other histological subtypes. The initial localizations were limb (44), uterine (32), retroperitoneal (23) and organs or bone (34). Patients received 900 mg/m2 of gemcitabine (days 1 and 8) over 90 min plus 100 mg/m2 of docetaxel (day 8), intravenously every 21 days. Gemcitabine/docetaxel combination was well tolerated with an overall response of 18.4% and with no clear statistical difference between leiomyosarcomas and other histological subtypes (24.2% versus 10.4% (p=0.06)). No difference was found between uterine soft-tissue sarcomas versus others. The median overall survival was 12.1 months (1-28). Better overall survival was correlated with leiomyosarcoma (p=0.01) and with the quality of the response, even for patients with stable disease (p<10(-4)). No statistical difference was found for the initial localization. Response to treatment and overall survival were better for patients in World Health Organization (WHO) performance status classification (PS) 0 at baseline versus patients in WHO PS-1, 2 or 3 (p=0.023 and p<10(-4), respectively). Gemcitabine/docetaxel combination was tolerable and demonstrated better response and survival for leiomyosarcoma, especially for patients in WHO PS-0 at baseline. For the other histological subtypes, the response was not encouraging, but the survival for patients in response or stable suggests further investigation.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Analysis of Variance, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Diarrhea, Drug Administration Schedule, Female, Humans, Leiomyosarcoma, Male, Middle Aged, Nausea, Neutropenia, Retrospective Studies, Sarcoma, Survival Analysis, Taxoids, Thrombocytopenia, Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/01/2008 8:32
Dernière modification de la notice
20/08/2019 16:04
Données d'usage